• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

肿瘤微环境的靶向转录组学分析揭示转移性骨肉瘤中的淋巴细胞排斥和血管功能障碍。

Targeted transcriptional profiling of the tumor microenvironment reveals lymphocyte exclusion and vascular dysfunction in metastatic osteosarcoma.

机构信息

Department of Translational Genomics, Keck School of Medicine of the University of Southern California, Los Angeles, CA, USA.

NanoString Technologies, Inc., Seattle, WA, USA.

出版信息

Oncoimmunology. 2019 Jun 27;8(9):e1629779. doi: 10.1080/2162402X.2019.1629779. eCollection 2019.

DOI:10.1080/2162402X.2019.1629779
PMID:31428529
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6685511/
Abstract

Osteosarcoma (OS) is the most common bone tumor in pediatric and adolescent/young adult patients yet little is known about the microenvironment that supports this aggressive disease. We have used targeted gene expression profiling and immunohistochemistry to characterize the microenvironment of metastatic and non-metastatic OS specimens from pediatric patients exhibiting poor histologic response to chemotherapy. Our results indicate that metastatic specimens exhibit lymphocyte exclusion as T cells are confined to the periphery of the pulmonary lesions. Furthermore, our data provides evidence of vascular dysfunction in metastatic OS indicated by increased expression of , an increased gene expression ratio, and decreased expression of , the gene encoding the adhesion molecule E-selectin. Moreover, correlation analyses show an inverse relationship between lymphocyte abundance and markers of vascular dysfunction exclusively in the metastatic specimens. Together, our data shows that the non-metastatic OS specimens demonstrate increased expression of various immunotherapeutic targets in comparison metastatic specimens and identifies vascular dysfunction and lymphocyte exclusion as important processes for therapeutic intervention in metastatic disease.

摘要

骨肉瘤(OS)是儿童和青少年/年轻成人患者中最常见的骨肿瘤,但对于支持这种侵袭性疾病的微环境知之甚少。我们使用靶向基因表达谱分析和免疫组织化学技术,对来自表现出对化疗不良组织学反应的儿科患者的转移性和非转移性 OS 标本的微环境进行了特征描述。我们的结果表明,转移性标本表现出淋巴细胞排斥现象,因为 T 细胞局限于肺病变的外围。此外,我们的数据提供了转移性 OS 血管功能障碍的证据,表现为 、基因表达比值增加和编码粘附分子 E-选择素的 基因表达减少。此外,相关分析显示,仅在转移性标本中,淋巴细胞丰度与血管功能障碍标志物之间存在反比关系。总之,我们的数据表明,与转移性标本相比,非转移性 OS 标本表现出各种免疫治疗靶标的表达增加,并确定血管功能障碍和淋巴细胞排斥是转移性疾病治疗干预的重要过程。

相似文献

1
Targeted transcriptional profiling of the tumor microenvironment reveals lymphocyte exclusion and vascular dysfunction in metastatic osteosarcoma.肿瘤微环境的靶向转录组学分析揭示转移性骨肉瘤中的淋巴细胞排斥和血管功能障碍。
Oncoimmunology. 2019 Jun 27;8(9):e1629779. doi: 10.1080/2162402X.2019.1629779. eCollection 2019.
2
Pathways of immune exclusion in metastatic osteosarcoma are associated with inferior patient outcomes.转移性骨肉瘤中免疫排斥的途径与患者预后不良相关。
J Immunother Cancer. 2021 May;9(5). doi: 10.1136/jitc-2020-001772.
3
Dysregulation of macrophage polarization is associated with the metastatic process in osteosarcoma.巨噬细胞极化失调与骨肉瘤的转移过程相关。
Oncotarget. 2016 Nov 29;7(48):78343-78354. doi: 10.18632/oncotarget.13055.
4
Progression of Osteosarcoma from a Non-Metastatic to a Metastatic Phenotype Is Causally Associated with Activation of an Autocrine and Paracrine uPA Axis.骨肉瘤从非转移表型向转移表型的进展与自分泌和旁分泌尿激酶型纤溶酶原激活物(uPA)轴的激活存在因果关联。
PLoS One. 2015 Aug 28;10(8):e0133592. doi: 10.1371/journal.pone.0133592. eCollection 2015.
5
Integrated transcriptomic analysis systematically reveals the heterogeneity and molecular characterization of cancer-associated fibroblasts in osteosarcoma.整合转录组分析系统地揭示了骨肉瘤中癌相关成纤维细胞的异质性和分子特征。
Gene. 2024 May 20;907:148286. doi: 10.1016/j.gene.2024.148286. Epub 2024 Feb 15.
6
Tumor Cell-Derived Angiopoietin-2 Promotes Metastasis in Melanoma.肿瘤细胞衍生的血管生成素 2 促进黑色素瘤转移。
Cancer Res. 2020 Jun 15;80(12):2586-2598. doi: 10.1158/0008-5472.CAN-19-2660. Epub 2020 Apr 17.
7
PD-L1 and IDO1 expression and tumor-infiltrating lymphocytes in osteosarcoma patients: comparative study of primary and metastatic lesions.PD-L1 和 IDO1 在骨肉瘤患者中的表达及肿瘤浸润淋巴细胞:原发灶与转移灶的对比研究。
J Cancer Res Clin Oncol. 2020 Oct;146(10):2607-2620. doi: 10.1007/s00432-020-03242-6. Epub 2020 May 9.
8
Tumor cell-targeted delivery of CRISPR/Cas9 by aptamer-functionalized lipopolymer for therapeutic genome editing of VEGFA in osteosarcoma.通过适配子功能化的脂质聚合物实现 CRISPR/Cas9 对肿瘤细胞的靶向递送,用于骨肉瘤中 VEGFA 的治疗性基因组编辑。
Biomaterials. 2017 Dec;147:68-85. doi: 10.1016/j.biomaterials.2017.09.015. Epub 2017 Sep 13.
9
Osteosarcoma cells exhibit functional interactions with stromal cells, fostering a lung microenvironment conducive to the establishment of metastatic tumor cells.骨肉瘤细胞与基质细胞之间存在功能相互作用,促进了有利于转移瘤细胞定植的肺部微环境。
Mol Biol Rep. 2024 Mar 29;51(1):467. doi: 10.1007/s11033-024-09315-w.
10
The Fas/FasL Signaling Pathway: Its Role in the Metastatic Process and as a Target for Treating Osteosarcoma Lung Metastases.Fas/FasL 信号通路:在转移过程中的作用及其作为治疗骨肉瘤肺转移的靶点。
Adv Exp Med Biol. 2020;1258:177-187. doi: 10.1007/978-3-030-43085-6_12.

引用本文的文献

1
Spatial Profiling Identifies Regionally Distinct Microenvironments and Targetable Immunosuppressive Mechanisms in Pediatric Osteosarcoma Pulmonary Metastases.空间分析揭示了儿童骨肉瘤肺转移中区域不同的微环境和可靶向的免疫抑制机制。
Cancer Res. 2025 Apr 2. doi: 10.1158/0008-5472.CAN-24-3723.
2
Spatial profiling identifies regionally distinct microenvironments and targetable immunosuppressive mechanisms in pediatric osteosarcoma pulmonary metastases.空间分析确定了小儿骨肉瘤肺转移中区域不同的微环境和可靶向的免疫抑制机制。
bioRxiv. 2025 Jan 24:2025.01.22.631350. doi: 10.1101/2025.01.22.631350.
3
Bayesian unsupervised clustering identifies clinically relevant osteosarcoma subtypes.贝叶斯无监督聚类可识别出具有临床相关性的骨肉瘤亚型。
Brief Bioinform. 2024 Nov 22;26(1). doi: 10.1093/bib/bbae665.
4
Characterization of the Rat Osteosarcoma Cell Line UMR-106 by Long-Read Technologies Identifies a Large Block of Amplified Genes Associated with Human Disease.应用长读长技术对大鼠骨肉瘤细胞系 UMR-106 的鉴定,发现了一大块与人类疾病相关的扩增基因。
Genes (Basel). 2024 Sep 26;15(10):1254. doi: 10.3390/genes15101254.
5
CDK4 is co-amplified with either TP53 promoter gene fusions or MDM2 through distinct mechanisms in osteosarcoma.在骨肉瘤中,细胞周期蛋白依赖性激酶4(CDK4)通过不同机制与TP53启动子基因融合体或MDM2共同扩增。
NPJ Genom Med. 2024 Sep 25;9(1):42. doi: 10.1038/s41525-024-00430-y.
6
Peripheral Soluble Immune Checkpoint-Related Proteins Were Associated with Survival and Treatment Efficacy of Osteosarcoma Patients, a Cohort Study.一项队列研究:外周可溶性免疫检查点相关蛋白与骨肉瘤患者的生存及治疗疗效相关
Cancers (Basel). 2024 Apr 24;16(9):1628. doi: 10.3390/cancers16091628.
7
Comparative Evaluation of Tumor-Infiltrating Lymphocytes in Companion Animals: Immuno-Oncology as a Relevant Translational Model for Cancer Therapy.伴侣动物肿瘤浸润淋巴细胞的比较评估:免疫肿瘤学作为癌症治疗的相关转化模型
Cancers (Basel). 2022 Oct 13;14(20):5008. doi: 10.3390/cancers14205008.
8
Recent Advances in Pediatric Cancer Research.儿科癌症研究的最新进展。
Cancer Res. 2021 Dec 1;81(23):5783-5799. doi: 10.1158/0008-5472.CAN-21-1191. Epub 2021 Sep 24.
9
Pathways of immune exclusion in metastatic osteosarcoma are associated with inferior patient outcomes.转移性骨肉瘤中免疫排斥的途径与患者预后不良相关。
J Immunother Cancer. 2021 May;9(5). doi: 10.1136/jitc-2020-001772.
10
Role of microRNAs in the crosstalk between osteosarcoma cells and the tumour microenvironment.微小RNA在骨肉瘤细胞与肿瘤微环境之间相互作用中的作用
J Bone Oncol. 2020 Sep 28;25:100322. doi: 10.1016/j.jbo.2020.100322. eCollection 2020 Dec.

本文引用的文献

1
Randomized Double-Blind Phase II Study of Regorafenib in Patients With Metastatic Osteosarcoma.随机双盲 II 期研究regorafenib 转移性骨肉瘤患者。
J Clin Oncol. 2019 Jun 1;37(16):1424-1431. doi: 10.1200/JCO.18.02374. Epub 2019 Apr 23.
2
Identification of candidate neoantigens produced by fusion transcripts in human osteosarcomas.鉴定人类骨肉瘤中融合转录本产生的候选新抗原。
Sci Rep. 2019 Jan 23;9(1):358. doi: 10.1038/s41598-018-36840-z.
3
Profiling targetable immune checkpoints in osteosarcoma.骨肉瘤中可靶向免疫检查点的分析
Oncoimmunology. 2018 Sep 11;7(12):e1475873. doi: 10.1080/2162402X.2018.1475873. eCollection 2018.
4
Efficacy and safety of regorafenib in adult patients with metastatic osteosarcoma: a non-comparative, randomised, double-blind, placebo-controlled, phase 2 study.regorafenib 在转移性骨肉瘤成人患者中的疗效和安全性:一项非比较、随机、双盲、安慰剂对照、2 期研究。
Lancet Oncol. 2019 Jan;20(1):120-133. doi: 10.1016/S1470-2045(18)30742-3. Epub 2018 Nov 23.
5
A Cancer Cell Program Promotes T Cell Exclusion and Resistance to Checkpoint Blockade.肿瘤细胞程序性死亡配体 1 表达促进 T 细胞排除和对检查点阻断的抵抗
Cell. 2018 Nov 1;175(4):984-997.e24. doi: 10.1016/j.cell.2018.09.006.
6
Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy.泛肿瘤基因组生物标志物用于基于 PD-1 检查点阻断的免疫治疗。
Science. 2018 Oct 12;362(6411). doi: 10.1126/science.aar3593.
7
The Tumor Vascular Endothelium as Decision Maker in Cancer Therapy.肿瘤血管内皮细胞在癌症治疗中作为决策者的作用
Front Oncol. 2018 Sep 10;8:367. doi: 10.3389/fonc.2018.00367. eCollection 2018.
8
T-cell inflamed tumor microenvironment predicts favorable prognosis in primary testicular lymphoma.T 细胞炎症性肿瘤微环境预测原发性睾丸淋巴瘤的预后良好。
Haematologica. 2019 Feb;104(2):338-346. doi: 10.3324/haematol.2018.200105. Epub 2018 Sep 20.
9
T Cell-Inflamed versus Non-T Cell-Inflamed Tumors: A Conceptual Framework for Cancer Immunotherapy Drug Development and Combination Therapy Selection.T 细胞炎症型与非 T 细胞炎症型肿瘤:癌症免疫治疗药物开发和联合治疗选择的概念框架。
Cancer Immunol Res. 2018 Sep;6(9):990-1000. doi: 10.1158/2326-6066.CIR-18-0277.
10
Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response.T 细胞功能障碍和耗竭的特征可预测癌症免疫疗法的反应。
Nat Med. 2018 Oct;24(10):1550-1558. doi: 10.1038/s41591-018-0136-1. Epub 2018 Aug 20.